A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014) (NCT07209111)
A Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as Monotherapy and in Combination With Cetuximab, in Participants With KRAS G12C-Mutant, Advanced Solid Tumors (KANDLELIT-014)
🩺 Plain-English Summary (8th-Grade Level)
Researchers want to learn if calderasib given alone or with cetuximab can treat certain advanced solid tumors in people with the KRAS G12C mutation. The goals of this study are to learn: * How many people have the cancer respond (get smaller or go away) to calderasib alone or with cetuximab and how these responses compare * About the safety of calderasib alone or with cetuximab and if people tolerate the treatments.
Who can join: Review the eligibility criteria below.
Location: Greater Baltimore Medical Center ( Site 1104) — Baltimore, Maryland
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (71 Sites)
Showing the first 25 of 71 sites.
- Greater Baltimore Medical Center ( Site 1104) — Baltimore, Maryland
- START Midwest ( Site 1103) — Grand Rapids, Michigan
- Comprehensive Cancer Centers of Nevada ( Site 1109) — Las Vegas, Nevada
- Rutgers Cancer Institute of New Jersey ( Site 1100) — New Brunswick, New Jersey
- START Mountain Region ( Site 1106) — West Valley City, Utah
- Virginia Cancer Specialists ( Site 1102) — Fairfax, Virginia
- Prince of Wales Hospital-Medical Oncology ( Site 1003) — Randwick, New South Wales
- Westmead Hospital ( Site 1000) — Westmead, New South Wales
- Epworth Freemasons ( Site 1004) — Melbourne, Victoria
- The Ottawa Hospital ( Site 2902) — Ottawa, Ontario
- Jewish General Hospital-CRU ( Site 2900) — Montreal, Quebec
- FALP ( Site 1200) — Santiago, Region M. de Santiago
- Centro de Oncología de Precisión ( Site 1202) — Santiago, Region M. de Santiago
- Clinica San Carlos de Apoquindo ( Site 1203) — Santiago, Region M. de Santiago
- Bradfordhill ( Site 1201) — Santiago, Region M. de Santiago
- Beijing Cancer hospital ( Site 1318) — Beijing, Beijing Municipality
- The First Affiliated Hospital of Xiamen University ( Site 1304) — Xiamen, Fujian
- Sun Yat-sen University Cancer Center ( Site 1303) — Guangzhou, Guangdong
- The first affiliated hospital, Sun Yat-Sen university ( Site 1329) — Guangzhou, Guangdong
- Harbin Medical University Cancer Hospital ( Site 1308) — Harbin, Heilongjiang
- Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 1326) — Wuhan, Hubei
- Hunan Cancer Hospital ( Site 1321) — Changsha, Hunan
- Hunan Cancer Hospital ( Site 1322) — Changsha, Hunan
- Jiangsu Province Hospital ( Site 1324) — Nanjing, Jiangsu
- The First Affiliated Hospital of Nanchang University ( Site 1307) — Nanchang, Jiangxi
📞 Contact the Study Coordinator
Phone: (888) 577-8839
Email: Trialsites@msd.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Neoplasm Malignant
- A Trial of a Multimodal Lifestyle Intervention to Optimize Survivorship After Cancer — Baton Rouge, Louisiana
- A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors — Duarte, California
- Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) — Tucson, Arizona
Explore by condition: All Neoplasm Malignant clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.